pocketful logo light
pocketful logo light
Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

NSE: NEULANDLAB BSE: 524558

₹16624

(0.99%)

Wed, 27 May 2026, 10:30 pm

mtf coin illustrationMTF 5x

Company History

1984

  • Neuland Laboratories Limited was incorporated as a private limited company.

1986

  • The company commenced operations at its plant at Bonthapally Village, Medak District, Andhra Pradesh.

1988

  • Neuland Drugs & Pharmaceuticals Private Limited was incorporated.

1990

  • The company expanded its installed capacity for salbutamol sulphate and its intermediates to 9 tpa.

1992

  • The company entered into an agreement with Indian Institute of Chemical Technology for process know-how for the manufacture of Ketorolac Tromethamine and Enalapril Maleate on December 2nd.

1993

  • The company completed a project for the manufacture of terbutaline sulphate, labetalol hydrochloride, and expanded the capacity of salbutamol sulphate to 18 tpa.
  • Neuland Drugs & Pharmaceuticals Private Limited was merged with Neuland Laboratories Limited as per the Scheme of Amalgamation approved by the High Court of Andhra Pradesh.

1994

  • The company completed a project for further diversifying its bulk drug manufacture and set up a new plant at I.D.A. Pashamylaram, Medak district, Andhra Pradesh.
  • Commercial production commenced in October 1994.
  • The company's equity issue of Rs.870 lacs was oversubscribed 70 times and the shares are listed on the Hyderabad and Bombay Stock Exchanges.

2009

  • Ms. Deepika Gupta joined as Company Secretary and compliance officer of the company.

2012

  • Neuland Laboratories Ltd issued rights in the ratio of 5:12.
  • The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.

2013

  • The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
  • Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.

2014

  • Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation.
  • The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each.
  • Neuland Laboratories announced rights in the ratio of 4:25.

2016

  • The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.

2017

  • Neuland Labs completed the acquisition of an API plant.